Quest Diagnostics Chooses Roche's Fully Automated, Real-Time HIV-1 Viral Load Monitoring Test For Its Customers in Laboratories Nationwide
Posted on: Monday, 19 May 2008, 12:00 CDT
INDIANAPOLIS, May 19 /PRNewswire/ -- Roche Diagnostics today announced that Quest Diagnostics , the nation's leading provider of diagnostic testing, information and services, has signed a multi-year agreement to use the COBAS(R) AmpliPrep / COBAS(R) TaqMan(R) HIV-1 Test for HIV viral load testing.
Physicians use the test information to monitor the effects of antiretroviral therapy by measuring changes in HIV-1 RNA levels. Roche's newest HIV-1 viral load monitoring test is the first fully automated real-time PCR test approved by the Food and Drug Administration.
"We are pleased to continue what has been a strong partnership since Quest Diagnostics first began using our molecular HIV test 12 years ago," said Whitney Green, Senior Vice-President for Molecular Diagnostics of Roche Diagnostics. "We share Quest Diagnostics' commitment to its physicians who need the most accurate testing information to make the best treatment decisions for their patients."
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007, sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested more than 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at http://www.roche.com/ .
For further information please contact: Lori McLaughlin Corporate Communications 317.521.3112 lori.mclaughlin@roche.com
Roche Diagnostics
CONTACT: Lori McLaughlin, Corporate Communications of Roche Diagnostics,+1-317-521-3112, lori.mclaughlin@roche.com
Web site: http://www.roche.com/
Source: PRNewswire
Related Articles
- Wireless Test Innovator Surpasses One Billion Devices Tested
- Response Biomedical Corporation Announces Strategic Partnership With Roche Diagnostics To Commercialize Cardiovascular Tests
- Roche Diagnostics, a World Leader in HIV Monitoring Tests, and ARK Diagnostics, Inc. Sign Letter of Intent to Commercialize ARK's HIV Drug Monitoring Products
- Roche Diagnostics' HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
- Roche Diagnostics' Test Helps Doctors Determine Appropriate Pain-Relief Treatment for Nursing Mothers
- Roche Diagnostics Announces Successful Resolution of Urgent Medical Device Correction Of CoaguChek PT Test Strips Used in Anticoagulation Monitoring
- Roche Diagnostics Submits West Nile Virus Blood Screening Test to FDA
- Roche Diagnostics Submits Hepatitis C Viral Load Monitoring Test to FDA
- Denver-Based UniPath Enters Agreement With Roche Diagnostics to Expand Cutting-Edge Molecular Medical Laboratory Testing
- New Blood Test for Management of Osteoporosis Cleared By the FDA; Roche Diagnostics' Test Aids Physicians and Patients in Monitoring Disease
 |
 |
User Comments (0)
RSS Feeds